Saturday 17 October 2026
Export ANRO’s income statement to Excel — free account
Alto Neuroscience, Inc.
ANRO Healthcare Biotechnology
In the quarter to June 2026, EPS was flat, free cash flow fell 43.4% and total debt fell 15.7%, each against the same quarter a year earlier.
22.07
0.55
−2.43%
Follow ANRO
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 3.56 | 1.60 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 24.00 | 20.91 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 63 | 63 | 76 | 68 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | 100.00 | — | — | — | — | |||||
| EBT | — | — | — | — | — | (9) | (28) | (36) | (61) | (63) | |||||
| EBT margin, % | — | — | — | — | — | (4,374.76) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | (9) | (28) | (36) | (61) | (63) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | 0 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | (3.81) | (8.04) | (9.73) | (2.50) | (2.19) | |||||
| Cash flow | — | — | — | — | — | (3.84) | (5.92) | (8.96) | (1.93) | (1.79) | |||||
| Capex | — | — | — | — | — | (0.28) | (0.21) | (0.13) | (0.08) | 0.00 | |||||
| Free cash flow | — | — | — | — | — | (4.12) | (6.13) | (9.09) | (2.01) | (1.80) | |||||
| Book value | — | — | — | — | — | 10.64 | 9.82 | 18.71 | 6.16 | 5.24 | |||||
| Shares, m | — | — | — | — | — | 2 | 3 | 4 | 25 | 29 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | — | — | — | — | ||||
| P/S | — | — | — | — | — | 0.00 | — | — | — | — | |||||
| P/B | — | — | — | — | — | 0.00 | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | 0.00 | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | (0.13) | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (9) | (20) | (33) | (47) | (52) | ||||
| Capex | — | — | — | — | — | (1) | (1) | 0 | (2) | 0 | |||||
| Free cash flow | — | — | — | — | — | (10) | (21) | (34) | (49) | (52) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 26 | 44 | 80 | 159 | 166 | ||||
| Total debt | — | — | — | — | — | — | 9 | 10 | 12 | 19 | |||||
| Net debt | — | — | — | — | — | (26) | (39) | (73) | (157) | (157) | |||||
| Shareholders’ equity | — | — | — | — | — | 26 | 34 | 70 | 151 | 151 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (69.58) | (52.81) | (46.51) | (34.92) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | 0.00 | 108.91 | 65.96 | (153.99) | (41.80) | |||||
Negative figures in brackets.
Fiscal years to Dec 2021
Charts ten years each
Alto Neuroscience, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics, Inc. | $901.0M | — (loss-making) | 4.8× | — | n/m | +33.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| AKTS Aktis Oncology, Inc. | $890.5M | — (loss-making) | — (loss-making) | — | n/m | −12.77% (below 0%: shrinking) | 100.00% | (853.99%) | Compare |
| ANRO Alto Neuroscience, Inc. | $887.7M | — (loss-making) | — | — | n/m | −43.41% (below 0%: shrinking) | — | 0.00% | |
| RIGL Rigel Pharmaceuticals, Inc. | $882.6M | 2.6× | 7.9× | −22.60% (below 0%: shrinking) | −72.07% (below 0%: shrinking) | −229.99% (below 0%: shrinking) | 89.17% | 29.95% | Compare |
| JBIO Jade Biosciences, Inc. | $875.1M | — (loss-making) | — | — | n/m | −115.11% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MLTX MoonLake Immunotherapeutics | $873.2M | — (loss-making) | — | — | n/m | −1.89% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GLUE Monte Rosa Therapeutics, Inc. | $863.4M | — (loss-making) | — (loss-making) | −61.33% (below 0%: shrinking) | n/m | −34.11% (below 0%: shrinking) | 100.00% | (547.84%) | Compare |
| KURA Kura Oncology, Inc. | $862.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| ALMS Alumis Inc. | $842.4M | — (loss-making) | — (loss-making) | −37.66% (below 0%: shrinking) | n/m | +23.59% (above 0%: growing) | 100.00% | (8,956.38%) | Compare |
| Median of peers | $874.1M | — | — | −30.13% | — | −23.44% | 99.42% | (174.88%) |
Alto Neuroscience, Inc. (ANRO) key facts
- Alto Neuroscience, Inc. (ANRO) is a Biotechnology company in the Healthcare sector, listed on the New York Stock Exchange.
- As of October 16, 2026, ANRO traded at $22.07, a market capitalization of $887.7 million.
- Return on equity was −41.8% and debt-to-equity 0.09.